Procainamide
Organica
1427 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Novocainamide has a membrane stabilizing effect.
Reduces the excitability and conductivity of the heart muscle, inhibits the formation of impulses in the foci of automatism, has a local anesthetic effect.
Indications
Applied with various violations of the heart rhythm:
Ventricular arrhythmias.
Extrasystole.
Paroxysmal ventricular tachycardia.
Supraventricular arrhythmias.
Paroxysmal atrial fibrillation or atrial flutter.
Composition
Novocainamide 0.25 g (250 mg).
No customer reviews for the moment.
Dosage and Administration
IM - 5–10 ml of 1–2% solution 3 times a week for a month, after which a 10-day break is taken.
For infiltration anesthesia, 0.25–0.5% solutions are used, for conductive and epidural - 2% solution; inside - 1/2 tsp (with pain).
Adverse reactions
From the central and peripheral nervous system: headache, dizziness, drowsiness, weakness, motor restlessness, loss of consciousness, convulsions, trismus, tremor, visual and auditory disturbances, nystagmus, horse tail syndrome (paralysis of the legs, paresthesia), paralysis of the respiratory muscles, impaired sensory and motor conduction, paralysis respiratory center often develops with subarachnoid anesthesia.
Contraindications
- hypersensitivity (including to para-aminobenzoic acid and other local anesthetics, esters),
- children's age (up to 18 years).
Carefully
Drug interactions
Local anesthetics increase the inhibitory effect on the central nervous system of other drugs. Anticoagulants (ardeparin sodium, dalteparin sodium, danaparoid sodium, enoxaparin sodium, heparin, warfarin) increase the risk of bleeding.
Pregnancy and Lactation
During periods of pregnancy and breastfeeding, the drug should be used when the benefit to the mother exceeds the risk to the fetus or child.
Special instructions
During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed.
Overdosage
Symptoms: pallor of the skin and mucous membranes, dizziness, nausea, vomiting, increased nervous irritability, cold sweat, tachycardia, decrease in blood pressure to almost collapse, tremor, convulsions, apnea, methemoglobinemia, respiratory depression, sudden cardiovascular, respiratory depression, sudden hemorrhage, apnea, methemoglobinemia, respiratory depression, sudden cardio-vascular
The effect on the central nervous system is manifested by a sense of fear, hallucinations, convulsions, motor agitation. In cases of overdose, the administration of the drug should be immediately stopped. When conducting local anesthesia, the site of injection can be tipped with adrenaline.
Treatment: general resuscitation measures that include inhalation of oxygen, if necessary, carrying out artificial ventilation of the lungs.
If convulsions continue for more than 15–20 sec, they are stopped by intravenous administration of thiopental (100–150 mg) or diazepam (5–20 mg).
In case of arterial hypotension and / or depression of the myocardium, ephedrine (15-30 mg) is injected intravenously, in severe cases, detoxification and symptomatic therapy.
In the event of intoxication after injection of novocaine into the muscles of the leg or arm, an urgent imposition of the harness is recommended to reduce the subsequent flow of the drug into the bloodstream.
- Brand name: Novocainamide pills 0.25 g
- Active ingredient: Procainamide
- Dosage form: Pills.
- Manufacturer: Organics
- Country of Origin: Russia
Studies and clinical trials of Procainamide (Click to expand)
- The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide
- Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy
- Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus
- Procainamide-induced thrombocytopenia
- Procainamide-induced agranulocytosis with reversible myeloid sensitivity
- Procainamide-associated pancytopenia
- Another case of procainamide induced pancytopenia
- Polyradiculoneuropathy accompaning procainamide-induced lupus erythematosus: Evidence for drug-induced enhanced sensitization to peripheral nerve myelin
- Cyclovinylogues of Procainamide
- Procainamide-induced serologic changes in asymptomatic patients
- Development of antibodies to ribonucleoprotein following short-term therapy with procainamide
- Cryoglobulins in the procainamide-induced lupus syndrome
- The implications of procainamide metabolism to its induction of lupus
- Procainamide-lymphocyte reactions. a possible explanation for drug-induced autoimmunity
- Antigen-specific suppressor cell activity in procainamide therapy
- Effects of long-term procainamide therapy on immunoglobulin synthesis
- Autoantigenic histone epitopes: a comparison between procainamide- and hydralazine-induced lupus
- N-acetylprocainamide is a less potent inducer of t cell autoreactivity than procainamide
- Serologic Evaluation of Patients Receiving Procainamide
- Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo
- Concentration-dependent clearance of procainamide in normal subjects
- Liquid chromatographic analysis of mexiletine in serum, with alternate application to tocainide, procainamide, and N-acetylprocainamide
- Synthesis of 4-[N- [2-(Methacryloyloxy) Ethoxycarbonyl) ]Amino-N′-[2- (Diethylamino) Ethyl]Benzamide; A Novel Polymerizable Derivative of Procainamide
- Synthesis of Some Low Molecular Weight Derivatives of Procainamide
8 other products in the same category:
arrow_upward